含奥沙利铂方案介入治疗中晚期肝癌的疗效研究  

Clinical effect of oxaliplatin-- containing regimen in TACE of advanced hepatocellular carcinoma

作　　者：孙玉梅[1] 张隆群[1] 杨小华[1] 周平[1] 

机构地区：[1]重庆医科大学附属第一医院肝胆外科,400016

出　　处：《现代护理（上旬版）》2007年第3期631-632,共2页Modern Nursing

摘　　要：目的探讨舍奥沙利铂方案介入治疗中晚期肝癌的疗效、不良反应。方法159例中晚期肝癌患者随机分2组。研究组79例，行含奥沙利铂方案介入治疗；对照组80例，行常规介入治疗，比较2组疗效和副作用。结果研究组瘤体缩小近期有效率为72．2％（57／79），较对照组51．3％（41／80）有显著性差异（P〈0．05）。研究组甲胎蛋白下降幅度分别为73．3％（33／45），较对照组43．1％有显著性差异（P〈0．05）。主要毒副反应为胃肠道反应及骨髓抑制。结论含奥沙利铂方案介入治疗期肝癌具有较高的疗效 毒反应发生率低。Objective To explore the clinical effect and side--effect of oxaliplatin-- containing regimen in TACE of advanced hepatocellular carcinoma. Methods 159 patients were divided randomly into experimental group （n=79, oxaliplatin＋EPI＋5-FU） and control group （n=80, MMC＋EP＋ 5-FU）. The clinical effect and side--effect of two groups were studied. Results The total effective rate of experimental group was 72.2% （57/79） ,and that of control group was 51.3% （41/80）, and the difference was significant （P〈0.05）. The descent rate of AFP.of experimental group was 73. 30/00 （33/45）, and that of control group was 43.1% （22/51 ）, and the difference was significant （P 〈 0.05 ）. The main side effects were gastrointestinal tract side--effect and leukopenia. Conclusions Oxaliplatin-- containing regimen in TACE of advanced hepatocellular carcinoma is an efficient method with fewer side effects.

关 键 词：原发性肝癌 介入治疗 奥沙利铂 护理 

分 类 号：R473.73[医药卫生—护理学]